Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™.

SCENARIO

Genenta was seeking to raise new capital to progress in the clinical studies in order to:

• advance the ongoing GBM clinical program
• conduct an Italian clinical Phase 2 synthetic controlled study of Temferon
• fund Temferon manufacturing activities for the Phase 2 trial

IL SUPPORTO DELL’ADVISOR

Growth Capital has advised Genenta’s management team.